stockrow
Friday 6 November 2026
Export PDEX’s income statement to Excel — free account
Pro-Dex, Inc.
PDEX Healthcare Medical Instruments & Supplies
Pro-Dex, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $77.5 million, up 16.5% from fiscal 2025.
- Revenue
- +11.0%
- EPS
- −33.6%
- Free cash flow
- +177.8%
- Total debt
- +42.2%
Quarter to September 2026, against a year earlier
62.75
1.55
+2.53%
Follow PDEX
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
11.09 | 13.28 | 13.84 | 18.40 |
P/S ratio |
1.73 | 2.11 | 2.44 | 2.78 | |
P/FCF ratio |
20.88 | 22.67 | 28.08 | 20.76 | |
P/Operating CF |
35.00 | 96.28 | (691.88) | 34.09 | |
P/B ratio |
3.00 | 3.48 | 3.97 | 4.48 | |
Price to Tangible BV |
3.00 | 4.14 | 4.67 | 5.25 | |
EV/Sales |
1.72 | 2.15 | 2.49 | 2.77 | |
EV/EBITDA |
9.86 | 13.26 | 13.39 | 14.80 | |
EV/Operating CF |
19.22 | 21.87 | 26.62 | 19.30 | |
EV/FCF |
20.74 | 23.15 | 28.67 | 20.69 | |
Quick Ratio |
2.21 | 2.10 | 2.40 | 2.45 | |
Current Ratio |
4.03 | 3.67 | 4.10 | 4.19 | |
Net Debt/EBITDA |
(0.23) | 0.96 | 1.00 | (0.18) | |
Debt/Assets |
12.86% | 19.08% | 17.80% | 16.02% | |
Debt/Equity |
0.19 | 0.32 | 0.28 | 0.25 | |
Asset Turnover |
1.18 | 1.07 | 1.14 | 1.13 | |
Operating CF/Net income |
1.63 | 0.41 | (0.10) | 2.13 | |
Capex/Depreciation |
(0.22) | (0.31) | (0.50) | (0.85) | |
Interest Coverage |
23.11 | 15.39 | 13.07 | 13.52 | |
Research and Development Expense of Revenue |
3.93% | 4.15% | 4.98% | 5.89% | |
Selling, General and Administrative Expense of Revenue |
9.38% | 11.09% | 12.48% | 10.37% | |
Intangible Assets out of Total Assets |
0.00 | 0.10 | 0.10 | 0.09 | |
Share Based Compensation of Revenue |
0.88% | 0.93% | 0.87% | 0.66% | |
Graham Net Nets |
0.23 | 0.15 | 0.14 | 0.12 | |
Graham Number |
31.63 | 34.29 | 37.49 | 36.04 | |
Earnings Yield |
9.02% | 7.53% | 7.22% | 5.43% | |
Free Cash Flow Yield |
4.79% | 4.41% | 3.56% | 4.82% | |
Revenue per Share |
5.74 | 6.23 | 6.33 | 6.41 | |
Operating CF per Share |
1.10 | 0.51 | (0.08) | 2.02 | |
Capex per Share |
(0.02) | (0.03) | (0.06) | (0.11) | |
Free Cash Flow per Share |
1.08 | 0.48 | (0.15) | 1.92 | |
Cash per Share |
2.71 | 3.43 | 2.90 | 4.05 | |
Shareholders Equity per Share |
12.81 | 14.12 | 14.77 | 15.39 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
12.81 | 14.12 | 14.77 | 15.39 | |
Free Cash Flow |
3.50 | 1.52 | (0.48) | 6.14 | |
Working Capital |
36.99 | 39.07 | 40.27 | 41.06 | |
Capital Expenditures |
(0.07) | (0.11) | (0.20) | (0.35) | |
Net Current Asset Value |
28.56 | 23.93 | 26.37 | 26.70 | |
EV/EBIT |
10.94 | 14.86 | 14.84 | 16.46 | |
Capex to Sales |
0.00 | 0.01 | 0.01 | 0.02 | |
Price to Operating Income |
11.01 | 14.55 | 14.54 | 16.51 | |
| Other line items | |||||
Average Receivables |
18.31 | 17.82 | 19.66 | 18.46 | |
Average Payables |
4.90 | 5.60 | 4.44 | 4.64 | |
Average Inventory |
20.66 | 22.89 | 21.84 | 21.73 | |
Average Assets |
61.32 | 69.63 | 67.85 | 70.44 | |
Average Common Equity |
36.73 | 40.24 | 42.13 | 45.43 |
Columns are period end dates · fundamentals updated 5 Nov 2026